X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs NATCO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA NATCO PHARMA ALEMBIC PHARMA/
NATCO PHARMA
 
P/E (TTM) x 21.1 13.7 154.3% View Chart
P/BV x 5.0 3.9 127.2% View Chart
Dividend Yield % 0.7 1.1 59.9%  

Financials

 ALEMBIC PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-18
NATCO PHARMA
Mar-18
ALEMBIC PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs6451,080 59.7%   
Low Rs470671 70.0%   
Sales per share (Unadj.) Rs166.1592.1 28.0%  
Earnings per share (Unadj.) Rs21.9188.4 11.6%  
Cash flow per share (Unadj.) Rs27.5206.3 13.3%  
Dividends per share (Unadj.) Rs4.008.25 48.5%  
Dividend yield (eoy) %0.70.9 76.2%  
Book value per share (Unadj.) Rs117.8833.6 14.1%  
Shares outstanding (eoy) m188.5236.90 510.9%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x3.41.5 227.0%   
Avg P/E ratio x25.54.6 547.7%  
P/CF ratio (eoy) x20.34.2 477.8%  
Price / Book Value ratio x4.71.1 450.6%  
Dividend payout %18.34.4 417.1%   
Avg Mkt Cap Rs m105,09032,311 325.2%   
No. of employees `000NA4.8 0.0%   
Total wages/salary Rs m6,2283,256 191.3%   
Avg. sales/employee Rs ThNM4,522.5-  
Avg. wages/employee Rs ThNM674.0-  
Avg. net profit/employee Rs ThNM1,439.0-  
INCOME DATA
Net Sales Rs m31,30821,848 143.3%  
Other income Rs m70404 17.4%   
Total revenues Rs m31,37822,252 141.0%   
Gross profit Rs m6,4319,284 69.3%  
Depreciation Rs m1,055662 159.3%   
Interest Rs m34154 22.1%   
Profit before tax Rs m5,4138,872 61.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m-810-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,2041,920 62.7%   
Profit after tax Rs m4,1286,952 59.4%  
Gross profit margin %20.542.5 48.3%  
Effective tax rate %22.221.6 102.7%   
Net profit margin %13.231.8 41.4%  
BALANCE SHEET DATA
Current assets Rs m18,24721,307 85.6%   
Current liabilities Rs m11,2355,920 189.8%   
Net working cap to sales %22.470.4 31.8%  
Current ratio x1.63.6 45.1%  
Inventory Days Days8673 116.8%  
Debtors Days Days61107 57.6%  
Net fixed assets Rs m20,03514,986 133.7%   
Share capital Rs m377369 102.2%   
"Free" reserves Rs m21,82430,353 71.9%   
Net worth Rs m22,20130,760 72.2%   
Long term debt Rs m5,0000-   
Total assets Rs m39,41137,151 106.1%  
Interest coverage x160.258.6 273.3%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.80.6 135.1%   
Return on assets %10.619.1 55.2%  
Return on equity %18.622.6 82.3%  
Return on capital %19.729.3 67.2%  
Exports to sales %46.40-   
Imports to sales %10.50-   
Exports (fob) Rs m14,535NA-   
Imports (cif) Rs m3,288NA-   
Fx inflow Rs m14,72210,322 142.6%   
Fx outflow Rs m7,0262,978 235.9%   
Net fx Rs m7,6967,343 104.8%   
CASH FLOW
From Operations Rs m3,1244,636 67.4%  
From Investments Rs m-8,844-11,155 79.3%  
From Financial Activity Rs m5,0266,509 77.2%  
Net Cashflow Rs m-693-18 3,851.7%  

Share Holding

Indian Promoters % 74.1 52.0 142.4%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 2.9 7.8 37.0%  
FIIs % 9.1 16.6 54.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 26.0 53.5%  
Shareholders   49,328 25,395 194.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Finish Flat; IT and Pharma Stocks Witness Selling(Closing)

Share markets in India ended their trading session on a flattish note. Sectoral indices ended on a mixed note with stocks in the IT sector and pharma sector witnessing most of the selling pressure.

Related Views on News

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Nov 14, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS